119 related articles for article (PubMed ID: 20400521)
1. The proapoptotic molecule BLID interacts with Bcl-XL and its downregulation in breast cancer correlates with poor disease-free and overall survival.
Broustas CG; Ross JS; Yang Q; Sheehan CE; Riggins R; Noone AM; Haddad BR; Seillier-Moiseiwitsch F; Kallakury BV; Haffty BG; Clarke R; Kasid UN
Clin Cancer Res; 2010 Jun; 16(11):2939-48. PubMed ID: 20400521
[TBL] [Abstract][Full Text] [Related]
2. Frequent loss of the BLID gene in early-onset breast cancer.
Cavalli LR; Noone AM; Makambi KH; Rone JD; Kasid UN; Haddad BR
Cytogenet Genome Res; 2011; 135(1):19-24. PubMed ID: 21846966
[TBL] [Abstract][Full Text] [Related]
3. BLID: A Novel Tumor-Suppressor Gene.
Yu X; Li Z
Oncol Res; 2014; 22(5-6):333-8. PubMed ID: 26629946
[TBL] [Abstract][Full Text] [Related]
4. Image cytometric bcl-2:bax and bcl-2:bcl-x ratios in invasive breast carcinoma: correlation with prognosis.
Schiller AB; Clark WS; Cotsonis G; Lawson D; DeRose PB; Cohen C
Cytometry; 2002 Aug; 50(4):203-9. PubMed ID: 12210599
[TBL] [Abstract][Full Text] [Related]
5. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.
Walter O; Prasad M; Lu S; Quinlan RM; Edmiston KL; Khan A
Hum Pathol; 2009 Nov; 40(11):1528-33. PubMed ID: 19695680
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of TNFAIP8 is associated with tumor aggressiveness and poor prognosis in patients with invasive ductal breast carcinoma.
Xiao M; Xu Q; Lou C; Qin Y; Ning X; Liu T; Zhao X; Jia S; Huang Y
Hum Pathol; 2017 Apr; 62():40-49. PubMed ID: 28087477
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical biomarkers in patients with early-onset breast carcinoma by tissue microarray.
Choi DH; Kim S; Rimm DL; Carter D; Haffty BG
Cancer J; 2005; 11(5):404-11. PubMed ID: 16259871
[TBL] [Abstract][Full Text] [Related]
8. Aberrant BLID expression is associated with breast cancer progression.
Li X; Su P; Liu X; Kong X; Zhang X; Zhang H; Yang Q
Tumour Biol; 2014 Jun; 35(6):5449-52. PubMed ID: 24532431
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
10. Survivin expression in breast carcinoma: correlation with apoptosis and prognosis.
Nassar A; Sexton D; Cotsonis G; Cohen C
Appl Immunohistochem Mol Morphol; 2008 May; 16(3):221-6. PubMed ID: 18301249
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors.
Tawfik K; Kimler BF; Davis MK; Fan F; Tawfik O
Hum Pathol; 2012 Jan; 43(1):23-30. PubMed ID: 21777944
[TBL] [Abstract][Full Text] [Related]
12. Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer.
Dahl E; En-Nia A; Wiesmann F; Krings R; Djudjaj S; Breuer E; Fuchs T; Wild PJ; Hartmann A; Dunn SE; Mertens PR
BMC Cancer; 2009 Nov; 9():410. PubMed ID: 19930682
[TBL] [Abstract][Full Text] [Related]
13. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
[TBL] [Abstract][Full Text] [Related]
14. NEDD4 expression is associated with breast cancer progression and is predictive of a poor prognosis.
Wan L; Liu T; Hong Z; Pan Y; Sizemore ST; Zhang J; Ma Z
Breast Cancer Res; 2019 Dec; 21(1):148. PubMed ID: 31856858
[TBL] [Abstract][Full Text] [Related]
15. Estrogen-responsive finger protein as a new potential biomarker for breast cancer.
Suzuki T; Urano T; Tsukui T; Horie-Inoue K; Moriya T; Ishida T; Muramatsu M; Ouchi Y; Sasano H; Inoue S
Clin Cancer Res; 2005 Sep; 11(17):6148-54. PubMed ID: 16144914
[TBL] [Abstract][Full Text] [Related]
16. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?
Kymionis GD; Dimitrakakis CE; Konstadoulakis MM; Arzimanoglou I; Leandros E; Chalkiadakis G; Keramopoulos A; Michalas S
J Surg Res; 2001 Aug; 99(2):161-8. PubMed ID: 11469882
[TBL] [Abstract][Full Text] [Related]
17. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells.
Milella M; Trisciuoglio D; Bruno T; Ciuffreda L; Mottolese M; Cianciulli A; Cognetti F; Zangemeister-Wittke U; Del Bufalo D; Zupi G
Clin Cancer Res; 2004 Nov; 10(22):7747-56. PubMed ID: 15570009
[TBL] [Abstract][Full Text] [Related]
19. Functional and biological analysis of Bcl-xL expression in human osteosarcoma.
Wang ZX; Yang JS; Pan X; Wang JR; Li J; Yin YM; De W
Bone; 2010 Aug; 47(2):445-54. PubMed ID: 20580954
[TBL] [Abstract][Full Text] [Related]
20. Aven blocks DNA damage-induced apoptosis by stabilising Bcl-xL.
Kutuk O; Temel SG; Tolunay S; Basaga H
Eur J Cancer; 2010 Sep; 46(13):2494-505. PubMed ID: 20619636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
